triazoles has been researched along with Soft Tissue Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MZ; Chor, S; Ciotti, GE; Egolf, S; Eisinger-Mathason, TSK; Grazioli, A; Haldar, M; Lawlor, MA; Lee, AC; Marino, GE; Niedzwicki, D; Pak, K; Park, PMC; Perry, JA; Qi, J; Rivera-Reyes, A; Shah, J; Weber, K; Xu, M; Ye, S | 1 |
| Abdul Razak, AR; Baker, S; Carlson, R; Condy, M; D'Angelo, SP; Dickson, MA; Ellis, J; Erinjeri, JP; Friedlander, S; Gounder, MM; Gupta, AA; Jasmine, FH; Kauffman, M; Keohan, ML; Loong, HH; Nyquist-Schultz, K; Rashal, T; Saint-Martin, JR; Salah, S; Schwartz, GK; Shacham, S; Tanner, L; Tap, WD; Unger, TJ; Zer, A | 1 |
| Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B | 1 |
| Benshahar, D; Capellaere, P; Kerbrat, P; Rouëssé, JG; Thomas, D; van Coninge, CJ; van Oosterom, AT | 1 |
1 trial(s) available for triazoles and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Capsules; Disease Progression; Drug Administration Schedule; Drug Compounding; Fasting; Female; Food-Drug Interactions; Humans; Hydrazines; Male; Middle Aged; New York City; Pharmaceutical Solutions; Postprandial Period; Sarcoma; Soft Tissue Neoplasms; Tablets; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazoles; Young Adult | 2016 |
3 other study(ies) available for triazoles and Soft Tissue Neoplasms
| Article | Year |
|---|---|
YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Topics: Adaptor Proteins, Signal Transducing; Angiomotins; Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hippo Signaling Pathway; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Microfilament Proteins; Muscle, Skeletal; NF-kappa B; Phosphoproteins; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Sarcoma; Signal Transduction; Soft Tissue Neoplasms; Transcription Factors; Triazoles; Ubiquitin-Specific Proteases; Vorinostat; YAP-Signaling Proteins | 2018 |
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Letrozole; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Prognosis; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Thrombocytopenia; Triazoles | 1987 |